← All trials
NCT06044194
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 21, 2023
- Primary completion
- Sep 30, 2023
- Completion date
- Oct 31, 2023
- First posted
- Sep 21, 2023
- Last posted
- Sep 21, 2023
- Enrollment
- 56
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- A.O. Ospedale Maggiore di LodiLead sponsor
- A.O. Ospedale Maggiore di LodiReponsible party - principal investigator
- A.O. Ospedale Maggiore di LodiSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.